Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Stock Downgraded to 'In-Line' by Evercore ISI

NEW YORK ­– Investment banking firm Evercore ISI has downgraded shares of Illumina to an In Line rating, with a price target of $340.

"We are downgrading Illumina to In Line as we see risks and upside surprises as being fairly balanced at current levels," analyst Vijay Kumar wrote in a research note.

"While we are huge fans of Illumina as a fundamental, secular growth company longer term, current valuation causes us to move to the sidelines," he added.

Previously, Evercore had rated the shares at Outperform with a price target of $330.

Kumar said Illumina "had a challenging 2019, with a few curveballs being thrown at the company," including declines in its microarray and direct-to-consumer business, headwinds in China, and delays in population genomics projects. Growth "never materialized," leading to a year of "misses and lowered guidance," Kumar wrote. "As we look towards 2020, we think the company is likely to start the year with a conservative outlook."

In morning trading on the Nasdaq, shares of Illumina were down 1 percent at $328.14.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.